Abcam, ab256126, Anti-Bcr-abl antibody [7C6] - BSA and Azide free

Size: 100µg / 1mg
Mouse Recombinant Monoclonal Bcr-abl antibody. Carrier free. Suitable for ICC/IF, WB and reacts with Human samples.
Key facts
Host species:Mouse,
Clonality:Monoclonal,
Clone number:7C6,
Isotype:IgG2a,
Carrier free:Yes,
Reacts with:Human,
Applications:WB, ICC/IFSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.,
Specificity:This antibody recognizes an epitope within the amino acid sequence SSINEEITPRRQS of Bcr/Abl.

Product details:
ab256126 is the carrier-free version of
ab187831
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The Bcr-abl fusion protein also known as BCR-ABL or BCR/c-ABL results from a genetic abnormality where parts of the BCR and ABL genes combine together. This fusion occurs on chromosome 22 known as the Philadelphia chromosome leading to a well-known oncogenic protein with a molecular mass of approximately 210 kDa. The Bcr-abl is primarily expressed in hematopoietic cells and plays a critical role in cellular proliferation and survival. The protein's kinase domain derived from c-ABL exhibits tyrosine kinase activity regulating downstream signaling pathways involved in cellular growth and division.
Biological function summary
Bcr-abl significantly alters normal cell functions by constantly activating signals that drive cell cycle progression and inhibit apoptosis. This protein forms a complex with various signaling molecules enhancing proliferative signals within the cell. The presence of BCR/ABL leads to abnormal interaction with cell cycle regulators and contributes to dysregulated growth characteristic of cancerous cells. Through these interactions Bcr-abl affects DNA repair processes and cytoskeletal remodelling both of which are critical for maintaining genomic stability and cellular integrity.
Pathways
Bcr-abl influences multiple signaling cascades prominently including the PI3K-AKT and RAS-RAF-MEK-ERK pathways. These pathways are pivotal for transmitting growth factor signals that promote cell survival and proliferation. BCR-ABL activates these pathways independently of growth factor binding which leads to uncontrolled proliferation and resistance to apoptosis. Additionally Bcr-abl interacts with proteins such as GRB2 and SHC which are parts of these signaling networks further amplifying growth and survival signals in affected cells.
Bcr-abl is strongly associated with chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL). These malignancies arise due to the continuous activity of the aberrant Bcr-abl protein which leads to the overproduction of malignant leukocytes. The disease progression in CML illustrates a link between the Bcr-abl expression and the transformation of normal hematopoietic stem cells into leukemic cells. Furthermore this protein relates to the development of leukemias by interacting with downstream effectors like STAT5 which aids in the transcription of anti-apoptotic genes further contributing to cancer cell survival and proliferation.